Lung Transplantation Clinical Trial
Official title:
Properties of Mesenchymal Stem Cells in Lung Transplant Candidates
The major limitation to long term survival in lung transplant recipients is the development
of graft failure over time, termed bronchiolitis obliterans. The conventional therapies used
to prevent rejection are not effective in preventing bronchiolitis obliterans. Therefore,
new therapies are needed to address this problem. A growing body of research has focused on
a unique population of bone marrow cells termed Mesenchymal Stem Cells (MSCs) to improve a
range of medical conditions including heart failure, autoimmune disease, and inflammatory
bowel disease. MSCs can prevent animal models of bronchiolitis obliterans. Because of this
information, it is plausible that MSCs could help patients as a potential treatment in lung
transplantation.
This proposal will test the immunologic properties of MSCs generated from such individuals
to answer the question of whether generation of whether it would be feasible to use such
cells in the future to prevent entities such as bronchiolitis obliterans.
The Investigator will approach patients who are being considered for a lung transplant
because of end stage lung disease. Enrolled patients will undergo a bone marrow aspiration
where a small amount of fluid is removed from their pelvic bone. Cells obtained in this
procedure will be expanded in the Emory/Georgia Tech Cell Lab. MSCs will be expanded in this
lab using cell culture conditions which are standardly used for MSCs.
Problem of Interest: Lung transplantation represents a potential therapy for patients with
end-stage lung diseases such as pulmonary fibrosis, emphysema and cystic fibrosis. The major
limitation to long term survival in lung transplant recipients is the development of graft
failure over time, termed bronchiolitis obliterans. The conventional therapies used to
prevent rejection are not effective in preventing bronchiolitis obliterans. Therefore, new
therapies are needed to address this problem. A growing body of research has focused on a
unique population of bone marrow cells termed Mesenchymal Stem Cells (MSCs) to improve a
range of medical conditions including heart failure, autoimmune disease, and inflammatory
bowel disease. MSCs can prevent animal models of bronchiolitis obliterans. Because of this
information, it is plausible that MSCs could help patients as a potential treatment in lung
transplantation. MSCs can be obtained from 2 sources: commercially available MSCs which are
generated from other normal volunteers and from the patient themselves. When MSCs are
obtained from the patient for whom they are used, they are termed "autologous MSCs". A major
potential drawback to the use of commercially available MSCs is that these cells contain
proteins from other individuals which could provoke rejection when used in lung transplant
recipients. Therefore, the use of autologous MSCs currently appears the most attractive
option. What is not understood at the present time is the extent to which autologous MSCs
obtained from chronically ill patients with end-stage lung disease still maintain properties
which would be beneficial. This proposal will test the immunologic properties of MSCs
generated from such individuals to answer the question of whether generation of whether it
would be feasible to use such cells in the future to prevent entities such as bronchiolitis
obliterans.
Overview on how this will be studied: The Investigator will approach patients who are being
considered for a lung transplant because of end stage lung disease. Enrolled patients will
undergo a bone marrow aspiration where a small amount of fluid is removed from their pelvic
bone. Cells obtained in this procedure will be expanded in the Emory/Georgia Tech Cell Lab.
MSCs will be expanded in this lab using cell culture conditions which are standardly used
for MSCs. The Investigator will test the efficiency of expansion of these MSCs to determine
if they can be obtained from all patients, or if there some patients demonstrate inefficient
MSC expansion based on age or disease or other factors. The Investigator will then test
in-vitro the ability of MSCs from different patients to prevent activation of the immune
system when faced with proteins from other individuals. The Investigator believes this model
system approximates the type of interaction that would occur if these MSCs were given to
patients who received a lung transplant.
Benefit of research to knowledge and human health: It is not presently known whether
patients with severe medical illness are able to have MSCs expanded. If it is found that
MSCs can be readily obtained from such individuals and additionally find that such MSCs have
properties which would be predicted to be beneficial in lung transplant, this study would
provide the rationale to use MSCs as a therapeutic agent in patients undergoing lung
transplantation.
;
Observational Model: Cohort, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02581111 -
Naloxone for Optimizing Hypoxemia Of Lung Donors
|
Phase 2/Phase 3 | |
Recruiting |
NCT02177916 -
Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation
|
N/A | |
Not yet recruiting |
NCT01394835 -
Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients
|
Phase 2 | |
Completed |
NCT01204970 -
Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients
|
N/A | |
Not yet recruiting |
NCT01162148 -
Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation
|
N/A | |
Active, not recruiting |
NCT00980967 -
Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study
|
N/A | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Recruiting |
NCT00163696 -
Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease
|
N/A | |
Completed |
NCT00177684 -
Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)
|
Phase 3 | |
Completed |
NCT00163891 -
Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients
|
N/A | |
Completed |
NCT03668483 -
Relation Between Muscle Strength With Exercise Capacity and Dyspnea in LTx
|
N/A | |
Not yet recruiting |
NCT02855372 -
Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT)
|
N/A | |
Completed |
NCT01211509 -
Montelukast in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Completed |
NCT01212406 -
Vitamin D in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Not yet recruiting |
NCT00808600 -
Empowerment of Lung and Heart-lung Transplant Patients
|
N/A | |
Completed |
NCT00553397 -
Live Lung Donor Retrospective Study
|
N/A | |
Completed |
NCT00402805 -
Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy
|
Phase 4 | |
Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
Terminated |
NCT00235651 -
Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients
|
Phase 3 | |
Active, not recruiting |
NCT02936505 -
Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.
|
N/A |